AYAL Capital Advisors Ltd Cuts Stock Holdings in Orthofix Medical Inc. $OFIX

AYAL Capital Advisors Ltd reduced its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 10.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 742,372 shares of the medical device company’s stock after selling 87,528 shares during the period. Orthofix Medical accounts for approximately 3.9% of AYAL Capital Advisors Ltd’s holdings, making the stock its 3rd biggest position. AYAL Capital Advisors Ltd owned approximately 1.87% of Orthofix Medical worth $11,254,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Rubric Capital Management LP lifted its stake in Orthofix Medical by 0.7% during the second quarter. Rubric Capital Management LP now owns 3,721,715 shares of the medical device company’s stock valued at $41,497,000 after purchasing an additional 26,769 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its stake in Orthofix Medical by 34.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock valued at $37,248,000 after purchasing an additional 858,900 shares during the last quarter. Juniper Investment Company LLC lifted its stake in Orthofix Medical by 15.3% during the third quarter. Juniper Investment Company LLC now owns 2,847,055 shares of the medical device company’s stock valued at $41,681,000 after purchasing an additional 377,729 shares during the last quarter. Millennium Management LLC lifted its stake in Orthofix Medical by 86.6% during the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock valued at $21,605,000 after purchasing an additional 684,850 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Orthofix Medical by 6.4% during the third quarter. Dimensional Fund Advisors LP now owns 1,142,545 shares of the medical device company’s stock valued at $16,726,000 after purchasing an additional 68,596 shares during the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Orthofix Medical

In related news, major shareholder Engine Capital Management, Lp purchased 112,950 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was acquired at an average price of $11.99 per share, with a total value of $1,354,270.50. Following the completion of the acquisition, the insider directly owned 3,783,131 shares in the company, valued at approximately $45,359,740.69. This trade represents a 3.08% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jorge Andres Cedron sold 3,743 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $12.82, for a total transaction of $47,985.26. Following the sale, the insider directly owned 59,006 shares of the company’s stock, valued at approximately $756,456.92. This trade represents a 5.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders bought 189,896 shares of company stock valued at $2,293,970 in the last ninety days. Insiders own 2.70% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on OFIX. Stifel Nicolaus cut their target price on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Canaccord Genuity Group reduced their price target on shares of Orthofix Medical from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Tuesday, April 21st. Barrington Research reduced their price target on shares of Orthofix Medical from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Friday, May 22nd. Finally, TD Cowen restated a “hold” rating on shares of Orthofix Medical in a research report on Thursday, May 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Orthofix Medical has an average rating of “Hold” and an average target price of $15.50.

Orthofix Medical Stock Performance

NASDAQ:OFIX opened at $9.23 on Thursday. Orthofix Medical Inc. has a 1 year low of $9.12 and a 1 year high of $16.99. The firm’s fifty day simple moving average is $11.22 and its 200 day simple moving average is $12.88. The company has a current ratio of 2.87, a quick ratio of 1.76 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $373.08 million, a PE ratio of -6.11 and a beta of 0.71.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings data on Tuesday, May 5th. The medical device company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.16. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The business had revenue of $196.71 million during the quarter, compared to analyst estimates of $196.40 million. On average, sell-side analysts anticipate that Orthofix Medical Inc. will post -1.48 EPS for the current year.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.